Existence of the diffusion- perfusion mismatch within 24 hours after onset of acute stroke: Dependence on proximal arterial occlusion

Radiology

Volumn 250, Issue 3, 2009, Pages 878-886

  Copen, William A ^a,b   Gharai, Leila Rezai ^a   Barak, Elizabeth R ^a   Schwamm, Lee H ^a   Wu, Ona ^a,b   Kamalian, Shahmir ^a   Gonzalez, R Gilberto ^a,b   Schaefer, Pamela W ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DESMOTEPLASE; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; IOPAMIDOL;

AGED; ARTICLE; BLOOD CLOT LYSIS; CLINICAL FEATURE; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONTROLLED STUDY; DIFFUSION WEIGHTED IMAGING; DRUG DOSE ESCALATION; FEMALE; HUMAN; INSTITUTIONAL REVIEW; INTERMETHOD COMPARISON; MAGNETIC RESONANCE ANGIOGRAPHY; MAJOR CLINICAL STUDY; MALE; OCCLUSIVE CEREBROVASCULAR DISEASE; PATIENT IDENTIFICATION; PERFUSION WEIGHTED IMAGING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STROKE; TUMOR VOLUME;

ACUTE DISEASE; AGED; CAROTID STENOSIS; CEREBRAL ANGIOGRAPHY; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; HUMANS; MALE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STROKE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 62649091305     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2503080811     Document Type: Article

References (43)

1. Tissue plasminogen activator for acute ischemic stroke: National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333:1581-1587.
2. Katzan IL, Furlan AJ, Lloyd LE, et al. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. JAMA 2000;283:1151-1158.
3. Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM. Why are stroke patients excluded from TPA therapy? an analysis of patient eligibility. Neurology 2001;56:1015-1020.
4. Cocho D, Belvis R, Marti-Fabregas J, et al. Reasons for exclusion from thrombolytic therapy following acute ischemic stroke. Neurology 2005;64:719-720.
5. SmithMA, DolisznyKM, ShaharE, McGovern PG, Arnett DK, Luepker RV. Delayed hospital arrival for acute stroke: the Minnesota Stroke Survey. Ann Intern Med 1998;129:190-196.
6. Kleindorfer D, Lindsell C, Brass L, Koroshetz W, Broderick J. National US estimates of re-combinant tissue plasminogen activator use: ICD-9 codes substantially underestimate. Stroke 2008;39:924-928.
7. O'Connor RE, McGraw P, Edelsohn L. Thrombolytic therapy for acute ischemic stroke: why the majority of patients remain ineligible for treatment. Ann Emerg Med 1999;33:9-14.
8. Kleindorfer D, Kissela B, Schneider A, et al. Eligibility for recombinant tissue plasmino-gen activator in acute ischemic stroke: a population-based study. Stroke 2004;35: e27-e29.
9. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017-1025.
10. Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II): Second European-Australasian Acute Stroke Study investigators. Lancet 1998;352:1245-1251.
11. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (alteplase) for is-chemic stroke 3 to 5 hours after symptom onset: the ATLANTIS Study - a randomized controlled trial. JAMA1999;282:2019-2026.
12. Ribo M, Molina CA, Rovira A, et al. Safety and efficacy of intravenous tissue plasmino- gen activator stroke treatment in the 3- to 6-hour window using multimodal transcra- nial Doppler/MRI selection protocol. Stroke 2005;36:602-606.
13. Hacke W, Albers G, Al-Rawi Y, et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005;36:66-73.
14. Furlan AJ, Eyding D, Albers GW, et al. Dose Escalation of Desmoteplase for Acute Ische mic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke 2006;37:1227-1231.
15. Sorensen AG, Copen WA, 0stergaard L, et al. Hyperacute stroke: simultaneous measurement of relative cerebral blood volume, relative cerebral blood flow, and mean tissue transit time. Radiology 1999;210:519-527.
16. Neumann-Haefelin T, Wittsack HJ, Wenserski F, et al. Diffusion- and perfu-sion-weighted MRI: the DWI/PWI mismatch region in acute stroke. Stroke 1999;30:1591-1597.
17. Darby DG, Barber PA, Gerraty RP, et al. Pathophysiologicaltopographyofacuteischemia by combined diffusion-weighted and perfusion MRI. Stroke 1999;30:2043-2052.
18. del Zoppo GJ, Poeck K, Pessin MS, et al. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol 1992;32:78-86.
19. Wolpert SM, Bruckmann H, Greenlee R, Wechsler L, Pessin MS, del Zoppo GJ. Neu-roradiologic evaluation ofpatients with acute stroke treated with recombinant tissue plas-minogen activator: the rt-PA Acute Stroke Study Group. AJNR Am J Neuroradiol 1993;14:3-13.
20. Jansen O, von Kummer R, Forsting M, Hacke W, Sartor K. Thrombolytic therapy in acute occlusion of the intracranial internal carotid artery bifurcation. AJNR Am J Neu-roradiol 1995;16:1977-1986.
21. Lee KY, Han SW, Kim SH, et al. Early recan-alization after intravenous administration of recombinant tissue plasminogen activator as assessed by pre- and post-thrombolytic an- giography in acute ischemic stroke patients. Stroke 2007;38:192-193.
22. Saqqur M, Uchino K, Demchuk AM, et al. Site of arterial occlusion identified by trans- cranial Doppler predicts the response to intravenous thrombolysis for stroke. Stroke 2007;38:948-954.
23. Zangerle A, Kiechl S, Spiegel M, et al. Re-canalization after thrombolysis in stroke patients: predictors and prognostic implications. Neurology 2007;68:39-44.
24. Reese TG, Heid O, Weisskoff RM, Wedeen VJ. Reduction of eddy-current-induced distortion in diffusion MRI using a twice-refo- cused spin echo. Magn Reson Med 2003;49:177-182.
25. Oslash;pstergaard L, Weisskoff RM, Chesler DA, Gyldensted C, Rosen BR. High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. I. Mathematical approach and statistical analysis. Magn Reson Med 1996;36:715-725.
26. Sette G, Baron JC, Mazoyer B, Levasseur M, Pappata S, Crouzel C. Local brain haemody-namics and oxygen metabolism in cerebro-vascular disease: positron emission tomography. Brain 1989;112:931-951.
27. Mihara F, Kuwabara Y, Tanaka A, et al. Reliability of mean transit time obtained using perfusion-weighted MR imaging: comparison with positron emission tomography. Magn Reson Imaging 2003;21:33-39.
28. Zaharchuk G. Theoretical basis of hemody-namic MR imaging techniques to measure cerebral blood volume, cerebral blood flow, and permeability. AJNR Am J Neuroradiol 2007;28:1850-1858.
29. Perthen JE, Calamante F, Gadian DG, Connelly A. Is quantification of bolus tracking MRI reliable without deconvolution? Magn Reson Med 2002;47:61-67.
30. Hossmann KA. Periinfarct depolarizations. Cerebrovasc Brain Metab Rev 1996;8:195-208.
31. Busch E, Gyngell ML, Eis M, Hoehn-Berlage M, Hossmann KA. Potassium-induced cortical spreading depressions during focal cerebral ischemia in rats: contribution to lesion growth assessed by diffusion-weighted NMR and biochemical imaging. J Cereb Blood Flow Metab 1996;16:1090-1099.
32. Barone FC, Feuerstein GZ. Inflammatory mediators and stroke: new opportunities for novel therapeutics. J Cereb Blood Flow Metab 1999;19:819- 834.
33. Nicotera P, Leist M, Fava E, Berliocchi L, Volbracht C. Energy requirement for caspase activation and neuronal cell death. Brain Pathol 2000;10:276-282.
34. Chan PH. Reactive oxygen radicals in signaling and damage in the ischemic brain. J Cereb Blood Flow Metab 2001;21:2-14.
35. Hartings JA, Rolli ML, Lu XC, Tortella FC. Delayed secondary phase of peri-infarct depolarizations after focal cerebral ischemia: relation to infarct growth and neuroprotection. J Neurosci 2003;23:11602-11610.
36. Kakuda W, Lansberg MG, Thijs VN, et al. Optimal definition for PWI/DWI mismatch in acute ischemic stroke patients. J Cereb Blood Flow Metab 2008;28:887-891. [Published correction appears in J Cereb Blood Flow Metab 2008;28:1272.]
37. Kidwell CS, Saver JL, Carneado J, et al. Predictors of hemorrhagic transformation in patients receiving intra-arterial thrombolysis. Stroke 2002;33:717-724.
38. Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004;363:768-774.
39. Lewandowski CA, Frankel M, Tomsick TA, et al. Combined intravenous and intra-arte-rial r-TPA versus intra-arterial therapy ofacute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial. Stroke 1999;30:2598-2605.
40. Ernst R, Pancioli A, Tomsick T, et al. Combined intravenous and intra-arterial recom-binant tissue plasminogen activator in acute ischemic stroke. Stroke 2000;31:2552-2557.
41. Zaidat OO, Suarez JI, Santillan C, et al. Response to intra-arterial and combined intravenous and intra-arterial thrombolytic therapy in patients with distal internal carotid artery occlusion. Stroke 2002;33:1821-1826.
42. IMS Study Investigators. Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study. Stroke 2004;35:904-911.
43. Sekoranja L, Loulidi J, Yilmaz H, et al. Intravenous versus combined (intravenous and intra-arterial) thrombolysis in acute ische-mic stroke: a transcranial color-coded duplex sonography- guided pilot study. Stroke 2006;37:1805-1809.